Literature DB >> 6917874

Bacteremia due to methicillin-resistant Staphylococcus aureus.

J P Myers, C C Linnemann.   

Abstract

During a three-year period, Staphylococcus aureus phage type D11/83A/85 that was resistant to methicillin, cephalothin, and multiple aminoglycosides was recovered from 260 infected patients in an urban general hospital in Cincinnati, Ohio. This methicillin-resistant S. aureus (MRSA) was recovered from 30% of all blood cultures positive for S. aureus and represented 50% of all episodes of nosocomial bacteremia due to S. aureus. Bacteremia due to MRSA occurred most often in surgical patients (especially burn patients), occurred late in hospitalization, and was recovered frequently from wounds and intravascular catheters. Infection with S. aureus was the direct cause of death of 44% of the patients with bacteremia due to MRSA. Nine of 10 MRSA-infected patients who were treated with vancomycin alone responded to therapy compared with seven of 15 who were treated with other antistaphylococcal antibiotics (P less than 0.05). The present study defines the epidemiologic characteristics of bacteremia due to MRSA, demonstrates the virulence of MRSA, and proves that vancomycin is effective as therapy.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6917874     DOI: 10.1093/infdis/145.4.532

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

1.  Rationale for eliminating Staphylococcus breakpoints for β-lactam agents other than penicillin, oxacillin or cefoxitin, and ceftaroline.

Authors:  Jennifer Dien Bard; Janet A Hindler; Howard S Gold; Brandi Limbago
Journal:  Clin Infect Dis       Date:  2014-01-22       Impact factor: 9.079

2.  Types of methicillin-resistant Staphylococcus aureus associated with high mortality in patients with bacteremia.

Authors:  T Nada; S Ichiyama; Y Iinuma; K Inuzuka; H Washida; M Ohta; K Shimokata; N Kato; N Nakashima
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-04       Impact factor: 3.267

Review 3.  Methicillin-resistant staphylococci: detection methods and treatment of infections.

Authors:  C J Hackbarth; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

4.  Epidemiologic aspects and results of applying the TRISS methodology in a Spanish trauma intensive care unit (TICU).

Authors:  J R Suárez-Alvarez; J Miquel; F J Del Río; P Ortega
Journal:  Intensive Care Med       Date:  1995-09       Impact factor: 17.440

5.  Clinical outcome with oral linezolid and rifampin following recurrent methicillin-resistant Staphylococcus aureus bacteremia despite prolonged vancomycin treatment.

Authors:  Jon-David Schwalm; Philippe El-Helou; Christine H Lee
Journal:  Can J Infect Dis       Date:  2004-03

6.  Epidemiology and clinical features of methicillin-resistant Staphylococcus aureus in the University Hospital, Jeddah, Saudi Arabia.

Authors:  Tariq A Madani
Journal:  Can J Infect Dis       Date:  2002-07

7.  Detection of the Staphylococcal mecA gene by chemiluminescent DNA hybridization.

Authors:  C P Kolbert; J E Connolly; M J Lee; D H Persing
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

8.  Risk factors for nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus.

Authors:  M Pujol; C Peña; R Pallares; J Ayats; J Ariza; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-01       Impact factor: 3.267

9.  Prospective study of infection, colonization and carriage of methicillin-resistant Staphylococcus aureus in an outbreak affecting 990 patients.

Authors:  R Coello; J Jiménez; M García; P Arroyo; D Minguez; C Fernández; F Cruzet; C Gaspar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-01       Impact factor: 3.267

10.  Therapy of staphylococcal infections with cefamandole or vancomycin alone or with a combination of cefamandole and tobramycin.

Authors:  L Coppens; B Hanson; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.